Tag archive for ‘glioblastoma multiforme’
Northwest Biotherapeutics: Still Another Rebuttal to a Feuerstein Attack Is Called For
Introduction Adam Feuerstein just published a blog that attacks the results and conclusions drawn from the paper summarizing results from the 51 patient information arm of the DCVax-L phase 3 trial. This marks the 22nd consecutive negative blog by Feuerstein on Northwest. I am growing tired of rebutting his articles, but as long as he […]
Refuting Feuerstein’s Latest Negative Blog on Northwest Biotherapeutics (NWBO, Buy, $7.56)
Before I Get Into This Article, a Word to My Subscribers I want to apologize to my subscribers for a software error that resulted in seven e-mails being sent out to alert subscribers that I had published a new company report today. There should have been just one. We have just implemented this e-mail alert […]
Northwest Biotherapeutics (NWBO, Buy, $7.59) What the 2014 10-K Had to Say about the Approval of DCVax-L under the German Early Access Program
Purpose of This Blog The approval of DCVax-L under the hospital exemption early access program was a stunning positive in my judgment. However, this is the first product made by an American company that has gained approval under this new law that was just passed in 2011. Because of this, there is obviously no prior […]
Highlighting A New Report on Dendritic Cell Cancer Vaccines
Northwest Biotherapeutics’ (NWBO) DCVax-L and ImmunoCellular Therapeutics’ ICT-107 are dendritic cell cancer vaccines that are in phase II trials for the treatment of glioblastoma multiforme, the most malignant form of brain cancer. Their dendritic cell technology is the same as that used by Dendreon’s Provenge. Importantly, NWBO and IMUC both have much more efficient manufacturing […]